Jordan A Torok1, Lin Gu2, Daniel J Tandberg3, Xiaofei Wang2, David H Harpole4, Chris R Kelsey3, Joseph K Salama3. 1. Department of Radiation Oncology, Duke University Medical Center, Durham, NC. Electronic address: jordan.torok@dm.duke.edu. 2. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC. 3. Department of Radiation Oncology, Duke University Medical Center, Durham, NC. 4. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.
Abstract
BACKGROUND: Patients with limited metastases, oligometastases (OMs), might have improved outcomes compared with patients with widespread distant metastases (DMs). The incidence and behavior of OMs from non-small-cell lung cancer (NSCLC) need further characterization. PATIENTS AND METHODS: The medical records of patients who had undergone surgery for stage I-III NSCLC from 1995 to 2009 were retrospectively reviewed. All information pertaining to development of the first metastatic progression was recorded and analyzed. Patients with DMs were categorized into OMs (1-3 lesions potentially amenable to local therapy) and DM subgroups. RESULTS: Of 1719 patients reviewed, 368 (21%) developed DMs with a median follow-up period of 39 months. A single lesion was diagnosed in 115 patients (31%) and 69 (19%) had 2 to 3 lesions (50% oligometastatic). The median survival from the DM diagnosis for oligometastatic and diffuse DM was 12.4 and 6.1 months, respectively (hazard ratio, 0.54; 95% confidence interval, 0.42-0.68; P < .001). Patients with a single metastasis had the longest median survival at 14.7 months. Younger age, OM, the use of chemotherapy for the primary tumor, and DM detection by surveillance imaging were independently associated with improved survival. CONCLUSION: DMs and OMs are common in surgically managed NSCLC. Overall survival appears to be prolonged with OM.
BACKGROUND:Patients with limited metastases, oligometastases (OMs), might have improved outcomes compared with patients with widespread distant metastases (DMs). The incidence and behavior of OMs from non-small-cell lung cancer (NSCLC) need further characterization. PATIENTS AND METHODS: The medical records of patients who had undergone surgery for stage I-III NSCLC from 1995 to 2009 were retrospectively reviewed. All information pertaining to development of the first metastatic progression was recorded and analyzed. Patients with DMs were categorized into OMs (1-3 lesions potentially amenable to local therapy) and DM subgroups. RESULTS: Of 1719 patients reviewed, 368 (21%) developed DMs with a median follow-up period of 39 months. A single lesion was diagnosed in 115 patients (31%) and 69 (19%) had 2 to 3 lesions (50% oligometastatic). The median survival from the DM diagnosis for oligometastatic and diffuse DM was 12.4 and 6.1 months, respectively (hazard ratio, 0.54; 95% confidence interval, 0.42-0.68; P < .001). Patients with a single metastasis had the longest median survival at 14.7 months. Younger age, OM, the use of chemotherapy for the primary tumor, and DM detection by surveillance imaging were independently associated with improved survival. CONCLUSION:DMs and OMs are common in surgically managed NSCLC. Overall survival appears to be prolonged with OM.
Authors: S A Laurie; S Banerji; N Blais; S Brule; P K Cheema; P Cheung; N Daaboul; D Hao; V Hirsh; R Juergens; J Laskin; N Leighl; R MacRae; G Nicholas; D Roberge; J Rothenstein; D J Stewart; M S Tsao Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Matthew Chan; David Palma; Aisling Barry; Andrew Hope; Richard Moore; Melissa O'Neil; Janet Papadakos; Devin Schellenberg; Tony Tadic; C Jillian Tsai; Meredith Giuliani Journal: Adv Radiat Oncol Date: 2020-06-18
Authors: Parth A Chodavadia; Corbin D Jacobs; Frances Wang; Joseph K Salama; Chris R Kelsey; Jeffrey M Clarke; Neal E Ready; Jordan A Torok Journal: Transl Lung Cancer Res Date: 2021-01
Authors: B C M Hermans; J L Derks; H J M Groen; J A Stigt; R J van Suylen; L M Hillen; E C van den Broek; E J M Speel; A-M C Dingemans Journal: Endocr Connect Date: 2019-12 Impact factor: 3.335